Related Experiment Video
Updated: Nov 10, 2025
Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
Published on: April 26, 2016
Dinaciclib, a Bimodal Agent Effective against Endometrial Cancer
David Howard1, David James1, Kate Murphy2
1Medical School, Swansea University, Singleton Park, Swansea SA2 8PP, UK.
Abstract:
Endometrial cancer (EC) is the sixth most prevalent female cancer globally and although high rates of success are achieved when diagnosed at an early stage, the 5-year survival rate for cancers diagnosed at Stages II-IV is below 50%. Improving patient outcomes will necessitate the introduction of novel therapies to the clinic. Pan-cyclin-dependent kinase inhibitors (CDKis) have been explored as therapies for a range of cancers due to their ability to simultaneously target multiple key cellular processes, such as cell cycle progression, transcription, and DNA repair. Few studies, however, have reported on their potential for the treatment of EC. Herein, we examined the effects of the pan-CDKi dinaciclib in primary cells isolated directly from tumors and EC cell lines. Dinaciclib was shown to elicit a bimodal action in EC cell lines, disrupting both cell cycle progression and phosphorylation of the RNA polymerase carboxy terminal domain, with a concomitant reduction in Bcl-2 expression. Furthermore, the therapeutic potential of combining dinaciclib and cisplatin was explored, with the drugs demonstrating synergy at specific doses in Type I and Type II EC cell lines. Together, these results highlight the potential of dinaciclib for use as an effective EC therapy.
Insights
Pan-cyclin-dependent kinase inhibitors (CDKIs) like dinaciclib show promise for treating advanced endometrial cancer (EC). This study found dinaciclib disrupts cancer cell growth and, when combined with cisplatin, demonstrates synergistic effects in EC treatment.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Endometrial cancer (EC) is a leading global cancer in women, with poor survival rates for advanced stages (II-IV).
- Novel therapeutic strategies are crucial for improving outcomes in advanced EC.
- Pan-cyclin-dependent kinase inhibitors (CDKIs) target fundamental cellular processes and are being investigated for various cancers.
Purpose of the Study:
- To evaluate the efficacy of the pan-CDKI dinaciclib in endometrial cancer.
- To investigate the combined therapeutic potential of dinaciclib and cisplatin in EC.
Main Methods:
- Treatment of primary tumor cells and EC cell lines with dinaciclib.
- Analysis of cell cycle progression and RNA polymerase phosphorylation.
- Assessment of Bcl-2 expression levels.
- Evaluation of combination therapy with dinaciclib and cisplatin in Type I and Type II EC cell lines.
Main Results:
- Dinaciclib demonstrated a dual mechanism of action in EC cell lines, inhibiting cell cycle progression and RNA polymerase phosphorylation.
- A reduction in Bcl-2 expression was observed following dinaciclib treatment.
- Synergistic effects were observed when dinaciclib was combined with cisplatin in both Type I and Type II EC cell lines.
Conclusions:
- Dinaciclib exhibits significant anti-cancer activity in endometrial cancer models.
- The combination of dinaciclib and cisplatin presents a promising synergistic therapeutic approach for EC.
- Dinaciclib holds potential as a novel therapy for endometrial cancer, particularly in advanced stages.
Related Concept Videos
02:34Inhibition of Cdk Activity
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:10Drugs that Destabilize Microtubules